149 related articles for article (PubMed ID: 37259689)
1. Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88.
Li Q; Wang L; Zhang J; Zhao G; Liu Z; Ma X; Jiang J
Clin Transl Sci; 2023 Jul; 16(7):1232-1242. PubMed ID: 37259689
[TBL] [Abstract][Full Text] [Related]
2. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
[TBL] [Abstract][Full Text] [Related]
3. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
Shah DK; Haddish-Berhane N; Betts A
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
[TBL] [Abstract][Full Text] [Related]
4. Preclinical safety profile of RC88-ADC:a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E.
Jiang J; Li S; Tang N; Wang L; Xin W; Li S
Drug Chem Toxicol; 2023 Jan; 46(1):24-34. PubMed ID: 34839761
[TBL] [Abstract][Full Text] [Related]
5. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
6. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
[TBL] [Abstract][Full Text] [Related]
7. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
Singh AP; Shah DK
AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
[TBL] [Abstract][Full Text] [Related]
8. A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human.
Singh R; Kozhich A; Pan C; Lee F; Cardarelli P; Vangipuram R; Iyer R; Marathe P
Biopharm Drug Dispos; 2020 Nov; 41(8-9):319-333. PubMed ID: 32678919
[TBL] [Abstract][Full Text] [Related]
9. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.
Gu Y; Sai Y; Wang J; Yu M; Wang G; Zhang L; Ren H; Fan S; Ren Y; Qing W; Su W
Eur J Pharm Sci; 2019 Aug; 136():104938. PubMed ID: 31132401
[TBL] [Abstract][Full Text] [Related]
11. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
[TBL] [Abstract][Full Text] [Related]
12. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model.
Li J; Chen R; Yao QY; Liu SJ; Tian XY; Hao CY; Lu W; Zhou TY
Acta Pharmacol Sin; 2018 Mar; 39(3):472-481. PubMed ID: 29119968
[TBL] [Abstract][Full Text] [Related]
15. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
17. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
18. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
[TBL] [Abstract][Full Text] [Related]
19. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Wang S; Guo P; Wang X; Zhou Q; Gallo JM
Mol Cancer Ther; 2008 Feb; 7(2):407-17. PubMed ID: 18281523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]